-
Product Insights
Hyperlipidemia: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperlipidemia - Global Clinical Trials Review, 2026" provides an overview of Hyperlipidemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Hyperlipidemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hyperlipidemia therapeutics. GlobalData epidemiologists estimate 128,720,003 total prevalent cases of high low-density lipoprotein C (LDL-C) with high triglycerides (TG) in 2024, which is expected to increase to 133,846,798 total prevalent cases in 2029. Most of the marketed hyperlipidemia assets, including both innovator molecules and generic molecules, are enzyme inhibitors, A total of 207 molecules are in development for hyperlipidemia, including 15 drugs in the pre-registration stage,...
-
Product Insights
Dyslipidemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Dyslipidemia Clinical Trial Report Overview A total of 3318 dyslipidemia clinical trials have been conducted as of July 2024. The dyslipidemia clinical trial report provides a comprehensive understanding of the dyslipidemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe · Asia-Pacific...
-
Product Insights
Dyslipidemia - Drugs In Development, 2024
Empower your strategies with our Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, and type 2 diabetes. Common...
-
Product Insights
Hyperlipidemia - Drugs In Development, 2024
Empower your strategies with our Hyperlipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperlipidemia is a medical condition characterized by elevated levels of lipids (fats) in the blood. This includes high levels of cholesterol and triglycerides. It is a significant risk factor for cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hyperlipidemia can be caused by genetic factors, an unhealthy diet high in saturated fats and cholesterol, sedentary lifestyle, obesity, and certain medical conditions...
-
Product Insights
Hypertriglyceridemia - Drugs In Development, 2024
Empower your strategies with our Hypertriglyceridemia – Drugs In Development, 2024 report and make more profitable business decisions. Hypertriglyceridemia is a condition in which the blood contains high levels of triglycerides, a type of fat that provides energy to the body. Triglycerides are important for normal metabolism, but excess amounts can increase the risk of cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hypertriglyceridemia can also cause acute pancreatitis, a serious inflammation of the pancreas that requires medical attention....
-
Product Insights
Mixed Dyslipidemia - Drugs In Development, 2024
Empower your strategies with our Mixed Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Dyslipidemia is a condition where the lipid levels in blood are either low or high. While in mixed dyslipidemia the levels of LDL (low density lipoprotein) and TG (triglycerides) are elevated, and HDL (high density lipoprotein) is low. This occurs when there is an overproduction of very low-density lipoprotein (VLDL) leading to an increase in LDL and TG. People with mixed dyslipidemia...
-
Product Insights
Hypertriglyceridemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hypertriglyceridemia Clinical Trial Report Overview A total of 701 Hypertriglyceridemia clinical trials were conducted as of December 2023. The Hypertriglyceridemia clinical trial report provides a comprehensive understanding of the Hypertriglyceridemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe · North America · ...
-
Sector Analysis
Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Dyslipidemia Market Report Overview The dyslipidemia market size across the 7MM was valued at $5.56 billion in 2022 and the market will achieve a CAGR of more than 10% during 2022-2032. The growth is attributed to the improved awareness about the health risks associated with dyslipidemia and growing efforts in screening and diagnosis are expected to lead to timely diagnosis of patients with this condition. Dyslipidemia Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Know More About the Dyslipidemia...
-
Sector Analysis
Dyslipidemia Epidemiology Analysis and Forecast to 2032
Dyslipidemia Epidemiology Analysis Report Overview In the 7MM, there were 287,608,383 diagnosed prevalent cases of Dyslipidemia in 2022. The cases are expected to achieve an AGR of less than 1% during the period 2022-2032. The following are some of the key highlights of the Dyslipidemia epidemiology analysis report: Of the 7MM, the US is expected to have the highest number of total prevalent cases, and Italy will have the lowest number of total prevalent cases of dyslipidemia in 2032. In...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.